Ophthalmic surgery (miosis): Intraocular: 0.5 mL instilled into anterior chamber before or after securing sutures
No dosage adjustment provided in manufacturer's labeling.
No dosage adjustment provided in manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Postmarketing:
Cardiovascular: Flushing
Dermatologic: Diaphoresis
Gastrointestinal: Abdominal cramps, epigastric discomfort, vomiting
Genitourinary: Bladder spasm
Nervous system: Headache
Ophthalmic: Blurred vision, corneal edema, corneal opacity, epithelial keratopathy (bullous), eye pain, increased intraocular pressure, iritis (postoperative), ocular hyperemia, ophthalmic inflammation, retinal detachment, visual impairment
Hypersensitivity to carbachol or any component of the formulation.
Disease-related concerns:
• Asthma: Use with caution in patients with asthma.
• Gastrointestinal disease: Use with caution in patients with peptic ulcer disease or gastrointestinal spasm.
• Heart failure: Use with caution in patients with acute heart failure. In a scientific statement from the American Heart Association, ophthalmic cholinergic agents have been determined to be agents that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).
• Hyperthyroidism: Use with caution in patients with hyperthyroidism.
• Parkinson disease: Use with caution in patients with Parkinson's disease.
• Urinary tract obstruction: Use with caution in patients with urinary tract obstruction.
Dosage form specific issues:
• Latex: Injection packaging may contain natural latex rubber.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intraocular [preservative free]:
Miostat: 0.01% (1.5 mL)
No
Solution (Miostat Intraocular)
0.01% (per mL): $33.72
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intraocular:
Miostat: 0.01% (1.5 mL)
Intraocular: Do not inject >0.5 mL into the anterior chamber. Instillation may occur before or after securing sutures. Sterile technique must be used.
Ophthalmic surgery: To obtain miosis during cataract surgery and reduce intraocular pressure following cataract surgery.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Cyclopentolate: May diminish the therapeutic effect of Carbachol. Risk C: Monitor therapy
Tropicamide: May diminish the therapeutic effect of Carbachol. Risk C: Monitor therapy
Reproduction studies have not been conducted.
It is not known if carbachol is excreted in breast milk. The manufacturer recommends that caution be exercised when administering carbachol to nursing women.
Synthetic direct-acting cholinergic agent that causes miosis by stimulating muscarinic receptors in the eye
Onset of action: Miosis: 2 to 5 minutes.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟